about
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsIntravoxel water diffusion heterogeneity MR imaging of nasopharyngeal carcinoma using stretched exponential diffusion model.Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers.Dosimetric predictors of radiation-induced acute nausea and vomiting in IMRT for nasopharyngeal cancer.Antifungal susceptibility and phenotypic characterization of oral isolates of a black fungus from a nasopharyngeal carcinoma patient under radiotherapyEGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma.Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma.Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma.Comparative analysis of dosimetric parameters of three different radiation techniques for patients with Graves' ophthalmopathy treated with retro-orbital irradiation.Personalized prediction of EGFR mutation-induced drug resistance in lung cancer.Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.Novel therapy for nasopharyngeal carcinoma--where are we.Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis.Personnel dose reduction in 90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward.PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma.Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma.Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.Post-radiation Plasma Epstein-Barr Virus DNA and Local Clinical Remission After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma.Radiation recall after capecitabine in a patient with recurrent nasopharyngeal carcinoma: a case report.Cervical nodal volume for prognostication and risk stratification of patients with nasopharyngeal carcinoma, and implications on the TNM-staging system.Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.The aftermath of LUX-Lung 7 study-what have we learnt from it?Patient dosimetry for 90Y selective internal radiation treatment based on 90Y PET imaging.Treatment outcomes of postradiation second head and neck malignancies managed by a multidisciplinary approach.Natural course and tumor doubling time of nasopharyngeal carcinoma. A study of 15 patients.Nasopharyngeal carcinoma: comparison of diffusion and perfusion characteristics between different tumour stages using intravoxel incoherent motion MR imaging.Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV.Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.Impact of intravenous contrast used in computed tomography on radiation dose to carotid arteries and thyroid in intensity-modulated radiation therapy planning for nasopharyngeal carcinoma.Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties.Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled TrialExtracapsular lymph node spread in recurrent nasopharyngeal carcinomaThe addition of pretreatment plasma Epstein-Barr virus DNA into the 8th edition of nasopharyngeal cancer TNM stage classificationEfficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using e
P50
Q28547357-A0898B1F-4484-40A9-BCCA-F61D22F061D7Q30881558-9D8271A8-F010-4407-A860-6987A3DAB0F7Q34052270-94D11142-5A8A-43CA-BA5D-68E554000539Q34247019-8E822A63-4D53-44AF-8022-941D3DE555F7Q35238239-7CFE160A-DD2B-4703-926A-EE2CA5FAE399Q35606916-B14EC0D1-3193-4493-80F1-7C320FA160C4Q36061130-77EC28C8-9EDB-4784-8A8B-B6F58467E715Q36326015-383F92F5-8955-45F2-A953-D728A3AA32D7Q36611697-AB6E23D7-AF2C-4C91-8896-680C8F14C7DEQ36614350-57CE39DE-98CF-4A40-A2EF-92050B084EBCQ37214412-6EC7CF42-4959-470E-804E-AB395BB3A8BFQ37705026-E728E0AA-7C49-4FBE-B6A9-09439ECA7553Q37706344-E7B9C9B9-F422-4B36-933D-DAADDA2C5C76Q38181765-3D5CCA70-BB25-41CE-943A-8799743EA144Q38430341-A2E4B52B-AFA6-4D03-A29E-43AA83C1675CQ38651333-4A5BF555-06E8-45B5-91BF-CC8F7EA3EA60Q38788767-CD0A21D0-EDDA-416F-99CF-16094B87FEACQ39088419-A47D5EB2-F722-48AA-829B-7FA43646F844Q40088346-FCFF3C35-7543-4878-8212-236972245C04Q40542708-AA6D60A3-01CA-4993-A5C0-BECD22B6B254Q40862682-DBE12941-CC13-4D57-B0AD-E8E1025F9FD1Q40945417-BA8F4253-108B-4B87-9A06-5B48D79961D8Q41040753-50BED488-ACC7-4057-93A7-83B0FD1B5A77Q41606792-9F862173-3125-4972-A23A-8747CF48B413Q41758054-06B7E3E4-E3F9-4AAB-9591-359207ADA504Q41812547-D748EF96-7F74-4456-84FB-9FB47D056A28Q44058512-A5D26E68-F7B8-494A-9352-F8672B9AEAB6Q44200583-EE07D33A-2709-4D2E-AF92-960D91D51805Q44827714-86D0DFCF-14FC-42D8-8C28-CE4D8968D882Q44963009-86459813-0A2D-45F9-8507-EAAF8967734BQ45843805-268212F6-4CB7-42C9-A0EA-BAE81E6607B7Q51527882-AA0FEB84-A117-4AFF-9C60-4F80EDA1DD04Q51743342-E74F0254-0B90-43A0-BB4B-DB289EB06AC6Q52672266-C44C6D8C-DB5F-4680-A0DC-3BD06E0A40AEQ52945867-FB6C4D3B-44D9-4326-AC26-5C6E46BAF0B6Q53499294-82CA76F3-3D97-4CB1-93BB-C6079F156025Q57176613-7AB6A552-629F-4898-B508-CACCD869931DQ59344110-9824D7E8-DCFF-4848-AF8F-8FC5C1BF02C1Q59353133-5ED4B587-A574-4139-B338-84F7897E5B46Q59652409-29F5D484-4AD6-42EE-BE5C-9F19084DA4F0
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Victor Ho Fun Lee
@en
Victor Ho Fun Lee
@nl
type
label
Victor Ho Fun Lee
@en
Victor Ho Fun Lee
@nl
prefLabel
Victor Ho Fun Lee
@en
Victor Ho Fun Lee
@nl
P31
P496
0000-0002-6283-978X